FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine. 1 and 2 objects represent a pharmaceutical composition and a kit for treating or preventing prostate cancer, containing RNA coding amino acid sequences containing kallikrein-2 (KLK2), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), Homeobox B13 (HOXB13), NK3 Homeobox 1 (NKX3-1), their immunogenic variants or immunogenic fragments or their immunogenic variants. 3 and 4 objects – use of the pharmaceutical composition or kit as a drug for treating or preventing prostate cancer. 5 object is a method of treating prostate cancer in a subject, comprising administering to the subject at least one RNA coding amino acid sequences containing kallikrein-2 (KLK2), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), Homeobox B13 (HOXB13), NK3 Homeobox 1 (NKX3-1), their immunogenic variants or immunogenic fragments or their immunogenic variants.
EFFECT: stimulation of proliferation/priming of T-cells and induction of antigen-specific T-cell response in a subject against prostate cancer cells expressing one or more specified tumour antigens.
83 cl, 20 dwg, 18 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC RNA FOR OVARIAN CANCER | 2020 |
|
RU2832172C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| DRUG CONJUGATES CONTAINING ANTI-CLAUDIN 18.2 ANTIBODIES | 2016 |
|
RU2841168C2 |
| IMMUNOGENIC FUSED PROTEIN | 2016 |
|
RU2757426C2 |
| VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS | 2014 |
|
RU2650860C2 |
